Related Experiment Video
Updated: Jan 14, 2026
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
12.5K
Drug therapy for acute ischaemic stroke: risks versus benefits
1Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Scotland. ril@skull.dcn.ed.ac.uk
Drug Safety
|November 24, 1998
Summary
Aspirin (acetylsalicylic acid) is now recommended for most acute ischemic stroke patients, offering a modest but substantial public health benefit. Other treatments like heparin and thrombolytic therapy show limited or conflicting results, requiring further research.
Area of Science:
- Neurology
- Clinical Trials
- Public Health
Background:
- Stroke is a prevalent medical emergency with limited treatment options until recently.
- Acute ischemic stroke management has evolved with new therapeutic evidence.
Purpose of the Study:
- To review current evidence on treatments for acute ischemic stroke.
- To assess the efficacy and indications of various stroke interventions.
Main Methods:
- Analysis of major clinical trials and published data on stroke treatments.
- Evaluation of aspirin, heparin, and thrombolytic therapies.
Main Results:
- Aspirin (acetylsalicylic acid) demonstrates a modest benefit for acute ischemic stroke, improving long-term independent survival.
- Heparin shows no net benefit due to increased hemorrhagic stroke risk.
- Thrombolytic therapy (alteplase) has conflicting trial results, with limited indications.
Conclusions:
- Aspirin is recommended for most acute ischemic stroke patients, providing significant public health benefits.
- Further large-scale trials are necessary to confirm benefits of other treatments and guide clinical practice.
- Organized stroke services and clinical trial participation are crucial for improving patient care.
Related Concept Videos
01:26Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
01:28Acute Coronary Syndrome IV: Interprofessional Care
214
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
214
01:29Venous Thrombosis III: Interprofessional Care
276
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
276
01:27Coronary Artery Disease V: Interprofessional Care
210
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
210
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K